口腔微生物组多样性对慢性乙型肝炎停用核苷(酸)类似物的影响
这项纵向研究分析了18例HBeAg阴性慢性乙型肝炎患者停用核苷(酸)类似物后的口腔微生物组,发现有利结局者从基线起α多样性持续较高且样本间变异较低,结合微生物标志物的随机森林模型预测性能优于临床标志物。
要点
- 停用NUC时口腔微生物组α多样性高与有利病毒学结局相关。
- 高HBsAg水平及不利结局与机会性菌群如副流感嗜血杆菌相关。
- 微生物标志物联合模型预测有利结局的AUC为0.79,优于临床标志物的0.66。
核心结论
- 在HBeAg阴性CHB患者停用NUC时,口腔微生物组谱可能有助于预测病毒学结局。
研究设计与样本
- 纵向探索性研究,纳入18例接受NUC治疗超过2年且计划停药的HBeAg阴性CHB患者。
- 分析110份唾液样本,覆盖7个时间点,随访36个月。
主要发现
- 有利结局者从基线起α多样性持续较高(P < .001),且所有时间点样本间变异较低(P < .05)。
- HBsAg、ALT和AST与若干普雷沃菌属 taxa 及特定通路呈负相关(Spearman ρ > -0.5,P < .01)。
- 不利结局和高HBsAg水平与机会性 taxa 副流感嗜血杆菌和Porphyromonas catoniae相关。
- 结合微生物标志物的随机森林模型预测有利与不利结局的AUC为0.79,临床标志物单独为0.66。
关键数值与推荐
- 有利结局定义为HBsAg消失或下降>1 log10或第3年持续停药后HBV DNA < 2000 IU/mL。
- 肝炎 flare 定义为ALT > 80 U/L或2倍基线水平。
临床怎么用
- 口腔微生物组分析或可辅助识别停用NUC后可能获得有利病毒学结局的HBeAg阴性CHB患者。
局限性
- 探索性研究,样本量小(18例患者),需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Withdrawal of nucleos(t)ide analogue (NUC) therapy in hepatitis B e antigen (HbeAg)-negative chronic hepatitis B (CHB) may lead to functional cure in a subset of patients. Although gut microbiota is known to influence both CHB progression and treatment outcomes, the oral microbiome in NUC cessation remains unexplored. METHODS: This longitudinal study explored the oral microbiome in patients with CHB on NUC therapy > 2 years having a planned NUC cessation. Oral microbiome composition was analyzed in 110 saliva samples across 7 time points from 18 HBeAg-negative patients with 36 months follow-up. Favorable outcome was defined as either HBsAg loss or decline of > 1 log10 or sustained off-therapy HBV DNA level < 2000 IU/mL during year 3. Hepatic flare was defined as alanine transaminase (ALT) > 80 U/L or 2 × baseline level. RESULTS: The overall microbial composition remained stable during the study period. Patients with favorable outcome showed consistently higher alpha diversities (P < .001) from baseline, with lower intersample variations across all time points (P < .05), compared to unfavorable. Hepatitis B surface antigen (HBsAg), ALT, and aspartate transaminase (AST) correlated inversely with several Prevotella taxa and specific pathways (Spearman ρ > -0.5, P < .01). Unfavorable outcome and high HBsAg level correlated with opportunistic taxa Haemophilus parainfluenzae and Porphyromonas catoniae. Random forest model incorporating validated microbial markers predicting favorable versus unfavorable outcome achieved higher predictive performance than clinical markers alone (area under curve, 0.79 vs 0.66). CONCLUSIONS: Our exploratory study suggests that oral microbiome profiling at NUC cessation in HBeAg-negative CHB could support prognostication of virological outcome. Clinical Trials Registration. NCT03681132.
引用
- Ghorbani M, Kvedaraite A, Al-Manei K, et al. Oral Microbiome Diversity Matters on Nucleos(t)ide Analogue Cessation in Chronic Hepatitis B. J Infect Dis. 2026. PMID: 41328917. doi:10.1093/infdis/jiaf591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。